Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Total Current Liabilities: 2019-2025

Historic Total Current Liabilities for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $31.8 million.

  • Allogene Therapeutics' Total Current Liabilities fell 2.27% to $31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.8 million, marking a year-over-year decrease of 2.27%. This contributed to the annual value of $35.5 million for FY2024, which is 4.20% down from last year.
  • Per Allogene Therapeutics' latest filing, its Total Current Liabilities stood at $31.8 million for Q3 2025, which was up 0.50% from $31.7 million recorded in Q2 2025.
  • Allogene Therapeutics' 5-year Total Current Liabilities high stood at $59.4 million for Q1 2023, and its period low was $30.0 million during Q1 2025.
  • In the last 3 years, Allogene Therapeutics' Total Current Liabilities had a median value of $35.5 million in 2024 and averaged $38.0 million.
  • The largest annual percentage gain for Allogene Therapeutics' Total Current Liabilities in the last 5 years was 104.52% (2021), contrasted with its biggest fall of 49.21% (2021).
  • Over the past 5 years, Allogene Therapeutics' Total Current Liabilities (Quarterly) stood at $47.9 million in 2021, then climbed by 12.15% to $53.7 million in 2022, then crashed by 30.99% to $37.1 million in 2023, then declined by 4.20% to $35.5 million in 2024, then decreased by 2.27% to $31.8 million in 2025.
  • Its Total Current Liabilities was $31.8 million in Q3 2025, compared to $31.7 million in Q2 2025 and $30.0 million in Q1 2025.